Advanced CKD Progression and Complications: A Comprehensive Management Scenario

Difficulty: Advanced

Format: Four-stage branching decision case with six-month evolution

Educational disclaimer: This case is for postgraduate education and does not replace individualized clinical judgment, local protocols, or current prescribing information.

Learning Objectives

Classify CKD using eGFR and albuminuria appropriately; recognize rapid progression and evaluate presumed diabetic kidney disease; select evidence-based kidney- and cardiovascular-protective therapies; manage anemia and CKD-mineral and bone disorder using trends and reversible-cause assessment; and plan kidney replacement therapy and transplant evaluation without initiating dialysis from eGFR alone.

Stage 1 — Initial nephrology assessment: stage, cause, and risk

Case presentation

Mr James Rodriguez is a 58-year-old man with a 12-year history of type 2 diabetes and an 8-year history of hypertension. Glycemic control has been suboptimal, with HbA1c values of 8.5–9.2% over the past two years. He takes metformin, glipizide, insulin glargine, lisinopril 20 mg daily, and hydrochlorothiazide 25 mg daily. Clinic blood pressure readings are usually 140–150/85–95 mmHg.

He is referred after an eGFR of 28 mL/min/1.73 m² and persistent proteinuria. Five years earlier, creatinine was 1.3 mg/dL with eGFR 58; three years earlier, creatinine was 1.8 mg/dL with eGFR 42; the current creatinine is 2.4 mg/dL with eGFR 28. The approximate decline of 10 mL/min/1.73 m² per year represents rapid progression. Urine protein-to-creatinine ratios have ranged from 1,200 to 1,800 mg/g for three years; UACR has not yet been measured.

He has no history of stones, recurrent urinary infection, or gross hematuria. His father had diabetes and kidney failure requiring dialysis. Mild diabetic retinopathy is documented.

Decision 1A — CKD classification

Choose the best initial classification.

CKD G2 because the eGFR was 58 five years ago.
CKD G4 with high-risk proteinuria, requiring UACR for albuminuria categorization.
Kidney failure requiring immediate dialysis because eGFR is below 30.
Acute kidney injury because creatinine has increased over time.

Preferred branch: CKD G4 with high-risk proteinuria, requiring UACR for albuminuria categorization.

Expert debrief: An eGFR of 28 is G4. A protein-to-creatinine ratio is not automatically interchangeable with UACR for KDIGO A-category assignment. Long-term data establish chronicity; the rapid decline signals high progression risk. eGFR alone is not an indication for dialysis.

Decision 1B — Cause evaluation

Obtain UACR, urinalysis with microscopy, renal ultrasound, medication review, and selected additional tests if atypical features emerge. Long-standing diabetes, hypertension, proteinuria, and retinopathy support presumed diabetic kidney disease, but active sediment, abrupt decline, systemic features, or unusual proteinuria should prompt evaluation for another or additional cause. Biopsy is selective, not automatic.

Decision 1C — Progression risk

Combine eGFR, UACR, trajectory, blood pressure, diabetes control, potassium, comorbidity, and a validated kidney-failure risk equation when applicable. Intensify disease-modifying therapy and begin kidney replacement education early.

Stage 2 — Complications: anemia and CKD-MBD

He reports fatigue. Hemoglobin is 9.8 g/dL, MCV 88 fL, TSAT 23%, and ferritin 180 ng/mL. Calcium is 8.9 mg/dL, phosphate 4.8 mg/dL, PTH 185 pg/mL, and 25-hydroxyvitamin D 18 ng/mL.

Decision 2A — Anemia work-up

Assess and correct reversible causes, including iron deficiency, blood loss, B12/folate deficiency, inflammation, and other clinically indicated causes. Consider iron therapy according to severity, tolerance, response, access, and local guidance. ESA treatment is individualized after correctable causes are addressed and is not triggered by hemoglobin alone.

Decision 2B — CKD-MBD

Interpret serial calcium, phosphate, PTH, and alkaline phosphatase values together. Correct nutritional vitamin D deficiency and address persistent or progressive phosphate elevation. A phosphate binder is not mandatory for a single mildly elevated phosphate value, and routine active vitamin D is not required for every non-dialysis patient.

Stage 3 — Slowing progression

Decision 3A — Kidney-protective pharmacotherapy

Use maximally tolerated ACE inhibition or ARB with creatinine and potassium monitoring. Consider an SGLT2 inhibitor because eGFR is above 20 if eligible. Consider finerenone if albuminuria persists despite optimized RAS blockade, potassium is normal, and monitoring is reliable. Consider a GLP-1 receptor agonist when additional glycemic and cardiovascular risk reduction is needed. Metformin should not be continued below eGFR 30.

Decision 3B — Blood pressure and diuretics

Confirm standardized and home blood-pressure readings, assess orthostatic symptoms and volume status, and add therapy according to response. Do not describe thiazide therapy as universally ineffective below eGFR 30; thiazide-like agents may retain value, while loop diuretics may be preferred for volume overload.

Decision 3C — Lifestyle and monitoring

Use sodium reduction, individualized protein intake, physical activity, weight management, smoking avoidance, medication review, sick-day safety education, and regular monitoring of eGFR/UACR, potassium, bicarbonate, hemoglobin, CKD-MBD indices, and symptoms.

Stage 4 — Six-month evolution and kidney replacement planning

At six months, blood pressure averages 135/82 mmHg, HbA1c is 7.8%, hemoglobin is 10.5 g/dL, and vitamin D has normalized. However, eGFR is now 15 mL/min/1.73 m², proteinuria remains high, and his family reports decreased appetite and subtle cognitive change.

Decision 4A — Interpretation of decline

Assess urgently for uremia and alternative causes of cognitive change, review volume and metabolic status, check medication toxicity, and accelerate kidney replacement planning. Dialysis initiation is symptom- and complication-based rather than determined by one eGFR threshold.

Decision 4B — Modality planning

Discuss home peritoneal dialysis, in-center hemodialysis, home hemodialysis, transplantation, and comprehensive conservative kidney care using shared decision-making. His interest in peritoneal dialysis should trigger timely education and planning, not an automatic commitment.

Decision 4C — Access and transplant evaluation

Begin transplant evaluation early when appropriate and plan access according to predicted need, modality, surgical assessment, and trajectory. For a rapidly progressing patient at eGFR 15 with possible uremic symptoms, the preparation window is narrow, but decisions should remain coordinated and patient-centered.

Expert synthesis

This case illustrates advanced CKD with presumed diabetic kidney disease, rapid eGFR decline, heavy proteinuria requiring UACR characterization, anemia, early CKD-MBD abnormalities, and emerging kidney-failure symptoms. The key principles are to use GFR and albuminuria together; evaluate atypical features; layer kidney-protective therapy; interpret anemia and CKD-MBD trends; and prepare early for transplant and kidney replacement therapy without initiating dialysis solely from eGFR.

Linked assessment: The accompanying Advanced self-assessment covers CKD progression, complications, and kidney replacement planning with detailed explanations at the end.

Sources: KDIGO 2024 CKD Guideline; KDIGO Diabetes and CKD guideline resources; KDIGO 2026 Anemia in CKD guideline resources.

Advanced Self-Assessment

Complete the 10-question Advanced CKD self-assessment below. Detailed explanations are provided after submission.

Advanced Self-Assessment: CKD Progression, Complications, and Kidney Replacement Planning

Advanced 10-question postgraduate self-assessment on CKD G4 classification, cause evaluation, rapid progression, layered kidney-protective therapy, anemia, CKD-MBD, uremic symptoms, and kidney replacement planning. Select the single best answer. Detailed clinical explanations are shown after the quiz.

1 / 10

The patient’s eGFR has declined from 58 to 28 over five years. Which interpretation is most appropriate?

The decline is compatible with rapid progression and warrants intensified risk assessment and closer monitoring.

The decline proves acute kidney injury.

The rate is too slow to influence treatment planning.

The decline is explained solely by age.

2 / 10

Which finding would most strongly prompt evaluation for a non-diabetic cause of CKD in a patient with long-standing diabetes?

Diabetic retinopathy with slowly increasing albuminuria

Persistent active urine sediment with dysmorphic erythrocytes or red-cell casts

Hypertension accompanying albuminuria

A family history of diabetes

3 / 10

A 58-year-old man with diabetes has an eGFR of 28 mL/min/1.73 m² and persistent urine protein-to-creatinine ratios of 1,200–1,800 mg/g. Which classification is most accurate at this visit?

CKD G2 A2

CKD G3a A3

CKD G4; obtain UACR to assign the albuminuria category

Kidney failure requiring immediate dialysis

4 / 10

Which statement best describes kidney replacement planning for this rapidly progressing patient?

Discuss transplantation, peritoneal dialysis, hemodialysis, and conservative care early, using shared decision-making.

Wait until emergency dialysis is required before discussing modalities.

Choose hemodialysis automatically because it is the most common modality.

Refer for transplant only after dialysis has begun.

5 / 10

At eGFR 15, the patient develops reduced appetite and subtle cognitive change. What is the most appropriate interpretation?

Dialysis must begin solely because the eGFR is 15.

The symptoms should prompt urgent assessment for uremia and competing causes while kidney replacement preparation is accelerated.

The symptoms are unrelated to kidney disease and require no evaluation.

Dialysis should be delayed until eGFR is below 5 in every patient.

6 / 10

After increasing lisinopril, which monitoring plan is most appropriate?

No laboratory follow-up is required if the blood pressure improves.

Check serum creatinine and potassium after the dose change and assess volume status and symptoms.

Stop ACE inhibition whenever creatinine rises by any amount.

Check only hemoglobin.

7 / 10

Which follow-up bundle is most appropriate for this patient with rapid progression and heavy proteinuria?

Annual creatinine alone.

Periodic eGFR and UACR, blood pressure review, potassium, bicarbonate, hemoglobin, CKD-MBD indices, medication safety, nutrition, symptoms, and kidney replacement readiness.

Hemoglobin only because anemia is the principal complication.

Follow-up only when symptoms become severe.

8 / 10

The patient has phosphate 4.8 mg/dL, calcium 8.9 mg/dL, PTH 185 pg/mL, and low 25-hydroxyvitamin D. Which statement is most accurate?

Start a phosphate binder for the single phosphate value regardless of trend.

Start routine calcitriol in all CKD G4 patients.

Interpret serial calcium, phosphate, PTH, and alkaline phosphatase values; correct vitamin D deficiency and address persistent phosphate elevation.

The normal calcium makes CKD-MBD impossible.

9 / 10

A patient with CKD G4 has hemoglobin 9.8 g/dL, TSAT 23%, ferritin 180 ng/mL, and fatigue. What is the best next approach?

Start ESA automatically because hemoglobin is below 10 g/dL.

Give a red-cell transfusion to every patient with CKD anemia.

Assess and correct reversible causes, consider iron therapy based on clinical context, and individualize any ESA decision.

Ignore the anemia because it is expected in CKD.

10 / 10

A patient with type 2 diabetes, albuminuric CKD, eGFR 28, and potassium 4.5 mmol/L is taking a maximally tolerated ACE inhibitor. Which additional therapy should be considered if no contraindication exists?

Stop RAS blockade and use a non-nephroprotective antihypertensive alone.

Add an SGLT2 inhibitor and consider finerenone if albuminuria persists and potassium monitoring is feasible.

Increase metformin above the usual renal-dose limits.

Avoid all glucose-lowering therapy until dialysis begins.

Your score is

The average score is 0%

By Wordpress Quiz plugin